ALPHAMAB ONCOLO.DL-000002 (3NK) — Working Capital to Net Assets Ratio

ALPHAMAB ONCOLO.DL-000002 (3NK) has a Working Capital to Net Assets ratio of 76.7% as of December 2025. Working capital of €1.31 Billion (current assets of €1.59 Billion minus current liabilities of €280.85 Million) is measured against net assets of €1.71 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See ALPHAMAB ONCOLO.DL-000002 defensive interval ratio to measure how many days the company can operate on defensive assets alone.